Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness

BMC Psychiatry
Pierre Michel LlorcaLudovic Samalin

Abstract

Long-acting injectable (LAI) formulations are not widely used in routine practice even though they offer advantages in terms of relapse prevention. As part of a process to improve the quality of care, the French Association for Biological Psychiatry and Neuropsychopharmacology (AFPBN) elaborated guidelines for the use and management of antipsychotic depots in clinical practice. Based on a literature review, a written survey was prepared that asked about 539 options in 32 specific clinical situations concerning 3 fields: target-population, prescription and use, and specific populations. We contacted 53 national experts, 42 of whom (79%) completed the survey. The options were scored using a 9-point scale derived from the Rand Corporation and the University of California in the USA. According to the answers, a categorical rank (first-line/preferred choice, second-line/alternate choice, third-line/usually inappropriate) was assigned to each option. The first-line option was defined as a strategy rated as 7-9 (extremely appropriate) by at least 50% of the experts. The following results summarize the key recommendations from the guidelines after data analysis and interpretation of the results of the survey by the scientific committee...Continue Reading

References

Feb 7, 1998·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J M KaneN R Schooler
Oct 3, 2001·The British Journal of Psychiatry : the Journal of Mental Science·C E AdamsA S David
Jan 28, 2004·The Journal of Clinical Psychiatry·Samuel J KeithHenry A Nasrallah
Aug 5, 2004·Psychiatric Services : a Journal of the American Psychiatric Association·Peter J WeidenJulie Locklear
Jul 2, 2005·Journal of Psychiatric Practice·S R McGurk
Dec 2, 2005·Journal of Psychiatric Practice·Michael H AllenUNKNOWN Expert Consensus Panel for Behavioral Emergencies 2005
Dec 30, 2006·The Journal of Clinical Psychiatry·Stephan HeresStefan Leucht
Dec 7, 2007·The Journal of Clinical Psychiatry·Troy A MooreAlexander L Miller
Apr 30, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Borah KimKi Hwan Yook
Oct 25, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Stephan HeresWerner Kissling
Jan 27, 2009·Clinical Therapeutics·Robin EmsleyJonathan Rabinowitz
Feb 10, 2009·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Mariam Hassan, Maureen J Lage
Mar 31, 2009·Journal of Psychopharmacology·G M Goodwin, UNKNOWN Consensus Group of the British Association for Psychopharmacology
Apr 16, 2009·Acta Psychiatrica Scandinavica. Supplementum·G S MalhiUNKNOWN CADE Clinic, University of Sydney
May 28, 2010·The British Journal of Psychiatry. Supplement·W Wolfgang Fleischhacker
May 28, 2010·The British Journal of Psychiatry. Supplement·Thomas R E BarnesCarol Paton
May 28, 2010·The British Journal of Psychiatry. Supplement·John M Kane, Carlos Garcia-Ribera
Nov 21, 2009·European Psychiatry : the Journal of the Association of European Psychiatrists·M LambertA Schreiner
Dec 4, 2009·Schizophrenia Bulletin·Robert W BuchananUNKNOWN Schizophrenia Patient Outcomes Research Team (PORT)
Feb 6, 2010·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Johannes HamannWerner Kissling
Jun 26, 2010·Journal of Affective Disorders·Luis Gutiérrez-RojasManuel Gurpegui
Dec 28, 2010·L'Encéphale·Pierre-Michel LlorcaLudovic Samalin
Dec 28, 2010·L'Encéphale·Pierre-Michel LlorcaUNKNOWN l’Association Française de Psychiatrie Biologique et Neuropsychopharmacologique (AFPBN)
Feb 5, 2011·Journal of Psychopharmacology·Thomas R E Barnes, UNKNOWN Schizophrenia Consensus Group of British Association for Psychopharmacology
Jul 16, 2011·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Emmanuel StipMarc-André Roy
Nov 15, 2011·The Journal of Clinical Psychiatry·Mark A FryeEduard Vieta
Dec 12, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN WFSBP Task force on Treatment Guidelines for Schizophrenia
Mar 14, 2013·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Heinz GrunzeUNKNOWN WFSBP Task Force on Treatment Guidelines for Bipolar Disorders
Jul 3, 2013·The Journal of Nervous and Mental Disease·Ludovic SamalinPierre-Michel Llorca

❮ Previous
Next ❯

Citations

Aug 25, 2015·Current Treatment Options in Psychiatry·Daniel C Javitt
Nov 21, 2014·International Journal of Psychiatry in Clinical Practice·Francesco PietriniAndrea Ballerini
Jan 14, 2016·Expert Opinion on Drug Safety·L SamalinPm Llorca
Jul 25, 2014·Human Psychopharmacology·Takefumi SuzukiMasaru Mimura
Aug 29, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Annie Killoran, Kevin M Biglan
Aug 6, 2015·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Yuan Hwa ChouYung-Chieh Yen
Apr 12, 2016·Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists·Tak Lam LoDavid Castle
Dec 3, 2014·European Psychiatry : the Journal of the Association of European Psychiatrists·S HeresR Vauth
Jul 22, 2016·European Psychiatry : the Journal of the Association of European Psychiatrists·F PietriniA Ballerini
Nov 22, 2016·International Journal of Molecular Sciences·Ludovic SamalinPierre-Michel Llorca
Dec 23, 2015·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Gabriela MatosRodrigo A Bressan
Feb 15, 2017·Journal of Clinical Psychopharmacology·Hans RittmannsbergerKurosch Yazdi
Dec 23, 2016·The Journal of Nervous and Mental Disease·Cynthia A BossieDong-Jing Fu
Nov 9, 2016·The Australian and New Zealand Journal of Psychiatry·Stanley Victor Catts, Brian Ignatius O'Toole
Nov 2, 2014·Therapeutic Advances in Psychopharmacology·Sofia BrissosVicent Balanzá-Martinez
Jan 15, 2020·International Journal of Psychiatry in Clinical Practice·Juan Carlos García ÁlvarezEnrique Pérez Martínez
Sep 26, 2017·Current Medical Research and Opinion·Kathleen BeusterienJohn F P Bridges
Apr 1, 2017·Clinical Drug Investigation·Stephane CheungSunny Tsukazawa
Jan 24, 2020·Frontiers in Psychiatry·Gloria GiordanoSergio De Filippis
Oct 17, 2018·NPJ Schizophrenia·Richard NewtonBenedicto Crespo-Facorro
Jun 30, 2018·European Psychiatry : the Journal of the Association of European Psychiatrists·Francesco PietriniAndrea Ballerini

❮ Previous
Next ❯

Methods Mentioned

BETA
SGA

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here